Partial Loss-of-Function Mutations in Insulin-Degrading Enzyme that Induce Diabetes also Impair Degradation of Amyloid β-Protein

Wesley Farris, Stefan Mansourian, Malcolm A. Leissring, Elizabeth A. Eckman, Lars Bertram, Christopher B. Eckman, Rudolph E. Tanzi, Dennis J. Selkoe

Research output: Contribution to journalArticle

185 Citations (Scopus)

Abstract

The causes of cerebral accumulation of amyloid β-protein (Aβ) in most cases of Alzheimer's disease (AD) remain unknown. We recently found that homozygous deletion of the insulin-degrading enzyme (IDE) gene in mice results in an early and marked elevation of cerebral Aβ. Both genetic linkage and allelic association in the IDE region of chromosome 10 have been reported in families with late-onset AD. For IDE to remain a valid candidate gene for late-onset AD on functional grounds, it must be shown that partial loss of function of IDE can still alter Aβ degradation, but without causing early, severe elevation of brain Aβ. Here, we show that naturally occurring IDE missense mutations in a well-characterized rat model of type 2 diabetes mellitus (DM2) result in decreased catalytic efficiency and a significant ∼15 to 30% deficit in the degradation of both insulin and Aβ. Endogenously secreted Aβ40 and Aβ42 are significantly elevated in primary neuronal cultures from animals with the IDE mutations, but there is no increase in steady-state levels of rodent Aβ in the brain up to age 14 months. We conclude that naturally occurring, partial loss-of-function mutations in IDE sufficient to cause DM2 also impair neuronal regulation of Aβ levels, but the brain can apparently compensate for the partial deficit during the life span of the rat. Our findings have relevance for the emerging genetic evidence suggesting that IDE may be a late-onset AD-risk gene, and for the epidemiological relationships among hyperinsulinemia, DM2, and AD.

Original languageEnglish (US)
Pages (from-to)1425-1434
Number of pages10
JournalAmerican Journal of Pathology
Volume164
Issue number4
StatePublished - Apr 2004
Externally publishedYes

Fingerprint

Insulysin
Amyloidogenic Proteins
Mutation
Alzheimer Disease
Brain
Genes
Serum Amyloid A Protein
Chromosomes, Human, Pair 10
Genetic Linkage
Hyperinsulinism
Missense Mutation
Type 2 Diabetes Mellitus
Rodentia
Insulin

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Farris, W., Mansourian, S., Leissring, M. A., Eckman, E. A., Bertram, L., Eckman, C. B., ... Selkoe, D. J. (2004). Partial Loss-of-Function Mutations in Insulin-Degrading Enzyme that Induce Diabetes also Impair Degradation of Amyloid β-Protein. American Journal of Pathology, 164(4), 1425-1434.

Partial Loss-of-Function Mutations in Insulin-Degrading Enzyme that Induce Diabetes also Impair Degradation of Amyloid β-Protein. / Farris, Wesley; Mansourian, Stefan; Leissring, Malcolm A.; Eckman, Elizabeth A.; Bertram, Lars; Eckman, Christopher B.; Tanzi, Rudolph E.; Selkoe, Dennis J.

In: American Journal of Pathology, Vol. 164, No. 4, 04.2004, p. 1425-1434.

Research output: Contribution to journalArticle

Farris, W, Mansourian, S, Leissring, MA, Eckman, EA, Bertram, L, Eckman, CB, Tanzi, RE & Selkoe, DJ 2004, 'Partial Loss-of-Function Mutations in Insulin-Degrading Enzyme that Induce Diabetes also Impair Degradation of Amyloid β-Protein', American Journal of Pathology, vol. 164, no. 4, pp. 1425-1434.
Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB et al. Partial Loss-of-Function Mutations in Insulin-Degrading Enzyme that Induce Diabetes also Impair Degradation of Amyloid β-Protein. American Journal of Pathology. 2004 Apr;164(4):1425-1434.
Farris, Wesley ; Mansourian, Stefan ; Leissring, Malcolm A. ; Eckman, Elizabeth A. ; Bertram, Lars ; Eckman, Christopher B. ; Tanzi, Rudolph E. ; Selkoe, Dennis J. / Partial Loss-of-Function Mutations in Insulin-Degrading Enzyme that Induce Diabetes also Impair Degradation of Amyloid β-Protein. In: American Journal of Pathology. 2004 ; Vol. 164, No. 4. pp. 1425-1434.
@article{b535bbae6db342439b14a8416dc65f2d,
title = "Partial Loss-of-Function Mutations in Insulin-Degrading Enzyme that Induce Diabetes also Impair Degradation of Amyloid β-Protein",
abstract = "The causes of cerebral accumulation of amyloid β-protein (Aβ) in most cases of Alzheimer's disease (AD) remain unknown. We recently found that homozygous deletion of the insulin-degrading enzyme (IDE) gene in mice results in an early and marked elevation of cerebral Aβ. Both genetic linkage and allelic association in the IDE region of chromosome 10 have been reported in families with late-onset AD. For IDE to remain a valid candidate gene for late-onset AD on functional grounds, it must be shown that partial loss of function of IDE can still alter Aβ degradation, but without causing early, severe elevation of brain Aβ. Here, we show that naturally occurring IDE missense mutations in a well-characterized rat model of type 2 diabetes mellitus (DM2) result in decreased catalytic efficiency and a significant ∼15 to 30{\%} deficit in the degradation of both insulin and Aβ. Endogenously secreted Aβ40 and Aβ42 are significantly elevated in primary neuronal cultures from animals with the IDE mutations, but there is no increase in steady-state levels of rodent Aβ in the brain up to age 14 months. We conclude that naturally occurring, partial loss-of-function mutations in IDE sufficient to cause DM2 also impair neuronal regulation of Aβ levels, but the brain can apparently compensate for the partial deficit during the life span of the rat. Our findings have relevance for the emerging genetic evidence suggesting that IDE may be a late-onset AD-risk gene, and for the epidemiological relationships among hyperinsulinemia, DM2, and AD.",
author = "Wesley Farris and Stefan Mansourian and Leissring, {Malcolm A.} and Eckman, {Elizabeth A.} and Lars Bertram and Eckman, {Christopher B.} and Tanzi, {Rudolph E.} and Selkoe, {Dennis J.}",
year = "2004",
month = "4",
language = "English (US)",
volume = "164",
pages = "1425--1434",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Partial Loss-of-Function Mutations in Insulin-Degrading Enzyme that Induce Diabetes also Impair Degradation of Amyloid β-Protein

AU - Farris, Wesley

AU - Mansourian, Stefan

AU - Leissring, Malcolm A.

AU - Eckman, Elizabeth A.

AU - Bertram, Lars

AU - Eckman, Christopher B.

AU - Tanzi, Rudolph E.

AU - Selkoe, Dennis J.

PY - 2004/4

Y1 - 2004/4

N2 - The causes of cerebral accumulation of amyloid β-protein (Aβ) in most cases of Alzheimer's disease (AD) remain unknown. We recently found that homozygous deletion of the insulin-degrading enzyme (IDE) gene in mice results in an early and marked elevation of cerebral Aβ. Both genetic linkage and allelic association in the IDE region of chromosome 10 have been reported in families with late-onset AD. For IDE to remain a valid candidate gene for late-onset AD on functional grounds, it must be shown that partial loss of function of IDE can still alter Aβ degradation, but without causing early, severe elevation of brain Aβ. Here, we show that naturally occurring IDE missense mutations in a well-characterized rat model of type 2 diabetes mellitus (DM2) result in decreased catalytic efficiency and a significant ∼15 to 30% deficit in the degradation of both insulin and Aβ. Endogenously secreted Aβ40 and Aβ42 are significantly elevated in primary neuronal cultures from animals with the IDE mutations, but there is no increase in steady-state levels of rodent Aβ in the brain up to age 14 months. We conclude that naturally occurring, partial loss-of-function mutations in IDE sufficient to cause DM2 also impair neuronal regulation of Aβ levels, but the brain can apparently compensate for the partial deficit during the life span of the rat. Our findings have relevance for the emerging genetic evidence suggesting that IDE may be a late-onset AD-risk gene, and for the epidemiological relationships among hyperinsulinemia, DM2, and AD.

AB - The causes of cerebral accumulation of amyloid β-protein (Aβ) in most cases of Alzheimer's disease (AD) remain unknown. We recently found that homozygous deletion of the insulin-degrading enzyme (IDE) gene in mice results in an early and marked elevation of cerebral Aβ. Both genetic linkage and allelic association in the IDE region of chromosome 10 have been reported in families with late-onset AD. For IDE to remain a valid candidate gene for late-onset AD on functional grounds, it must be shown that partial loss of function of IDE can still alter Aβ degradation, but without causing early, severe elevation of brain Aβ. Here, we show that naturally occurring IDE missense mutations in a well-characterized rat model of type 2 diabetes mellitus (DM2) result in decreased catalytic efficiency and a significant ∼15 to 30% deficit in the degradation of both insulin and Aβ. Endogenously secreted Aβ40 and Aβ42 are significantly elevated in primary neuronal cultures from animals with the IDE mutations, but there is no increase in steady-state levels of rodent Aβ in the brain up to age 14 months. We conclude that naturally occurring, partial loss-of-function mutations in IDE sufficient to cause DM2 also impair neuronal regulation of Aβ levels, but the brain can apparently compensate for the partial deficit during the life span of the rat. Our findings have relevance for the emerging genetic evidence suggesting that IDE may be a late-onset AD-risk gene, and for the epidemiological relationships among hyperinsulinemia, DM2, and AD.

UR - http://www.scopus.com/inward/record.url?scp=1642290835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642290835&partnerID=8YFLogxK

M3 - Article

C2 - 15039230

AN - SCOPUS:1642290835

VL - 164

SP - 1425

EP - 1434

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 4

ER -